



BioLineRx to Present at the Annual Roth Conference in California

March 6, 2015

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 27th Annual Roth Conference being held at the Ritz Carlton in Dana Point, CA.

The BioLineRx presentation is scheduled to start at 10:00 a.m. PDT (13:00 p.m. EDT) on Tuesday, March 10, 2015. A live audio webcast of the presentation will be available online at [BioLineRx's events web page](#). An archive of the event will also be available for those unable to listen live.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial scheduled for completion in mid-2015; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.

In December 2014, BioLineRx entered into a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept for potential future licensing by Novartis.

For more information on BioLineRx, please visit www.bioglinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Source: BioLineRx

[Tiberend Strategic Advisors, Inc.](#)

Joshua Drumm, Ph.D.

(212) 375-2664

jdrumm@tiberend.com

or

Andrew Mielach

(212) 375-2694

amielach@tiberend.com

or

Tsipi Haitovsky

Public Relations

+972-3-6240871

tsipih@netvision.net.il